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Background
Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year follow-up [1] [2] [3] . Moreover, both ranibizumab and pegaptanib sodium have been effective in refractory CRVO-ME or BRVO-ME case series of patients who had previous bevacizumab and/or triamcinolone injections [4, 5] . There are no randomized clinical trial data on anti-VEGF agents in ischemic subgroup CRVO-ME and the use of anti-VEGF agents to treat this condition therefore remains anedoctal.
Case Presentation
A 73-year old caucasian man, with a general medical history of diabetes and systemic hypertension and an ophthalmic history of non-ischemic Central Retinal Vein Occlusion (CRVO) with cystoid macular edema (CME) in his right eye in December 2008, was referred to our division on January 2011. The patient had undergone 3 triamcinolon injections in 2009 and a Panretinal Photocoagulation after an ischemic shift. The ophthalmic examination showed in this eye a visual acuity of 20/2000, a C2N1 cataract (based on Lens Opacities Classification System III) and an exudative macular detachment. The left eye was normal with a visual acuity of 20/20. We performed fluorescein angiography and Optical Coherence Tomography (OCT3 Stratus, Carl Zeiss, Dublin, CA), the latter showing a foveal thickness of 1718 µm, measured by caliper (Figures 1 and 2 ). On 02/09/2011, once obtained the informed consent, a 0.5 mg ranibizumab intravitreal injection (Lucentis®, Novartis, Basel, Switzerland) was carried out in the right eye. 15 and 25 days later, we repeated the OCT, that showed no changes; the visual acuity was unchanged as well. Due to the In our refractory ischemic CRVO-ME patient, pegaptanib sodium showed prompt clinical response. In some cases, even if it is selective for the VEGF 165 isoform only, pegaptanib sodium could represent a further possibility in such a therapeutic challenge. patient's demands, and on the basis of the usually rapid improvement, within 7 days, in visual acuity and foveal thickness in the CRUISE study (ranibizumab), and of the small series from Udaondo et al. [3, 5] (Figures 3 and 4) . Three months later, foveal profile and visual acuity were unchanged.
Conclusion
It is difficult to individuate if the lack of efficacy of ranibizumab in this case is due to the block of the neuroprotectant isoforms of VEGF necessary for the adaptative response of retinal neurons to ischemic injury or if another "trigger" is involved with the pegaptanib response.
Anyway, the observation that, in our refractory ischemic CRVO-ME patient, pegaptanib sodium showed prompt clinical response, may suggest that at least in some cases this drug could represent a further possibility in such a therapeutic challenge.
Moreover, even if today dexamethasone intravitreal implant has a specific indication for the treatment of macular edema following CRVO, anti-VEGF therapy could well maintain a role due to minimal collateral effects, at least for glaucoma patients or in combination treatments.
